)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
CervoMed
CervoMed (CRVO) investor relations material
CervoMed Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary6 Jul, 2026
Company overview and business model
Clinical-stage biotechnology company focused on treatments for age-related brain disorders, with lead candidate neflamapimod targeting neuroinflammation and synaptic dysfunction.
Neflamapimod is in clinical development for dementia with Lewy Bodies (DLB), non-fluent variant primary progressive aphasia, stroke recovery, and ALS.
Holds a new patent for neflamapimod in DLB patients without substantial AD-like tau pathology, providing IP protection into 2042.
Financial performance and metrics
Closed a registered direct offering in June 2026, raising $10.0 million gross proceeds at $4.00 per share.
Private Placement in June 2026 raised approximately $10.5 million gross proceeds at $3.14 per unit.
Use of proceeds and capital allocation
Will not receive proceeds from resale of shares by selling stockholders; proceeds from warrant exercises (if any) will be used for working capital and general corporate purposes.
Potential proceeds from full cash exercise of Series B and C Warrants total approximately $21.8 million.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CervoMed
- Advancing neflamapimod to Phase 3 in DLB, with strong efficacy, financing, and regulatory alignment.CRVO
7th Annual HCW Neuro Perspectives Hybrid Conference19 Jun 2026 - Neflamapimod shows strong, durable efficacy in DLB without AD co-pathology, Phase 3 planned.CRVOCorporate presentation15 Jun 2026
- Net loss rose to $8.0 million in Q1 2026, with cash runway concerns and pending trial milestones.CRVOQ1 202618 May 2026
- Board recommends approval of all proposals, including a 2M-share increase to the equity plan.CRVOProxy filing30 Apr 2026
- Phase III DLB trial with biomarker-driven selection set after strong Phase II results and regulatory alignment.CRVOThe 38th Annual Roth Conference30 Apr 2026
- Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months.CRVOQ4 202517 Mar 2026
- Neflamapimod achieved robust, durable efficacy in DLB without AD co-pathology, advancing to Phase 3.CRVOCorporate presentation13 Mar 2026
- Therapeutic advances in DLB show robust efficacy, with phase III and major funding planned.CRVOH.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026
- Neflamapimod targets early DLB with biomarker-driven trials aiming for rapid, meaningful benefit.CRVOStatus Update3 Feb 2026
Next CervoMed earnings date
Q2 20267 Aug, 2026
CervoMed
Next CervoMed earnings date
Q2 20267 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage